Preclinical Evidence Supports Sotagliflozin's Superior Efficacy In Attenuating Salt-induced Kidney Damage

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to dainty type 2 diabetes, person important heart- and kidney- protective effects. In the kidney, SGLT2 reabsorbs approximately 97% offiltered glucose in the S1 and S2 segments of the proximal tubule, while SGLT1reabsorbs the remainder successful nan S3 segment.

In investigation conducted successful rats, investigators recovered that dual inhibition of SGLT1 and SGLT2 much efficaciously reduces salt-sensitive hypertension and kidney wounded than SGLT2 inhibition alone. The findings will beryllium presented astatine ASN Kidney Week 2025 November 5–9.

Salt-sensitive hypertension-elevated humor unit owed to excess brackish consumption- affects astir half of individuals pinch precocious humor unit and substantially contributes to kidney disease, cardiovascular complications, and progression to kidney failure. When researchers compared selective SGLT2 inhibition (through curen pinch dapagliflozin) with dual SGLT1/2 inhibition(through treatment with sotagliflozin) in a well-established rat exemplary of salt-induced hypertension and chronic kidney disease, they recovered that some narcotics had profound effects connected slowing nan progression of salt-induced hypertension.

Compared with selective SGLT2 inhibition, dual SGLT1/2 inhibition produceda greater simplification successful mean arterial unit and much efficaciously attenuated kidney injury, although it had no impact on blood pressure under normal-saltconditions. Sotagliflozin also reduced body weight, enhanced urinary sodiumand chloride excretion, and nearly doubled fractional glucose excretion compared pinch dapagliflozin. Neither curen altered kidney function. SGLT2 inhibition modulated respective metabolic pathways successful a region-specific mode successful nan kidney, pinch pronounced effects connected lipid metabolism and inflammatory signaling.

Our study provides preclinical evidence supporting the expanded use of dualSGLT1/2 inhibitors beyond bosom nonaccomplishment and diabetes, extending their imaginable into hypertension management, peculiarly successful salt-sensitive patients."

Olha Kravtsova, University of South Florida

"These findings besides found a instauration for further investigation into location kidney metabolism. Moreover, they item lipid and inflammatory pathways arsenic promising therapeutic targets successful nan curen of hypertension."